Hesam Khodadadi1,2, Évila Lopes Salles1,2, Abbas Jarrahi3, Fairouz Chibane4, Vincenzo Costigliola5, Jack C Yu6, Kumar Vaibhav3, David C Hess7, Krishnan M Dhandapani3, Babak Baban1,2,7. 1. Department of Oral Biology and Diagnostic Sciences, Dental College of Georgia, Augusta University, Augusta, Georgia, USA. 2. Center for Excellence in Research, Scholarship and Innovation, Dental College of Georgia, Augusta, Augusta University, Augusta, Georgia, USA. 3. Department of Neurosurgery, Medical College of Georgia, Augusta University, Augusta, Georgia, USA. 4. Department of Surgery, Medical College of Georgia, Augusta University, Augusta, Georgia, USA. 5. European Medical Association (EMA), Brussels, Belgium. 6. Children's Hospital of Georgia, Medical College of Georgia, Augusta University, Augusta, Georgia, USA. 7. Department of Neurology, Medical College of Georgia, Augusta University, Augusta, Georgia, USA.
Abstract
Introduction: In the absence of effective antivirals and vaccination, the pandemic of COVID-19 remains the most significant challenge to our health care system in decades. There is an urgent need for definitive therapeutic intervention. Clinical reports indicate that the cytokine storm associated with acute respiratory distress syndrome (ARDS) is the leading cause of mortality in severe cases of some respiratory viral infections, including COVID-19. In recent years, cannabinoids have been investigated extensively due to their potential effects on the human body. Among all cannabinoids, cannabidiol (CBD) has demonstrated potent anti-inflammatory effects in a variety of pathological conditions. Therefore, it is logical to explore whether CBD can reduce the cytokine storm and treat ARDS. Materials and Methods: In this study, we show that intranasal application of Poly(I:C), a synthetic analogue of viral double-stranded RNA, simulated symptoms of severe viral infections inducing signs of ARDS and cytokine storm. Discussion: The administration of CBD downregulated the level of proinflammatory cytokines and ameliorated the clinical symptoms of Poly I:C-induced ARDS. Conclusion: Our results suggest a potential protective role for CBD during ARDS that may extend CBD as part of the treatment of COVID-19 by reducing the cytokine storm, protecting pulmonary tissues, and re-establishing inflammatory homeostasis. Copyright 2020, Mary Ann Liebert, Inc., publishers.
Introduction: In the absence of effective antivirals and vaccination, the pandemic of COVID-19 remains the most significant challenge to our health care system in decades. There is an urgent need for definitive therapeutic intervention. Clinical reports indicate that the cytokine storm associated with acute respiratory distress syndrome (ARDS) is the leading cause of mortality in severe cases of some respiratory viral infections, including COVID-19. In recent years, cannabinoids have been investigated extensively due to their potential effects on the human body. Among all cannabinoids, cannabidiol (CBD) has demonstrated potent anti-inflammatory effects in a variety of pathological conditions. Therefore, it is logical to explore whether CBD can reduce the cytokine storm and treat ARDS. Materials and Methods: In this study, we show that intranasal application of Poly(I:C), a synthetic analogue of viral double-stranded RNA, simulated symptoms of severe viral infections inducing signs of ARDS and cytokine storm. Discussion: The administration of CBD downregulated the level of proinflammatory cytokines and ameliorated the clinical symptoms of Poly I:C-induced ARDS. Conclusion: Our results suggest a potential protective role for CBD during ARDS that may extend CBD as part of the treatment of COVID-19 by reducing the cytokine storm, protecting pulmonary tissues, and re-establishing inflammatory homeostasis. Copyright 2020, Mary Ann Liebert, Inc., publishers.
Authors: Niall D Ferguson; Eddy Fan; Luigi Camporota; Massimo Antonelli; Antonio Anzueto; Richard Beale; Laurent Brochard; Roy Brower; Andrés Esteban; Luciano Gattinoni; Andrew Rhodes; Arthur S Slutsky; Jean-Louis Vincent; Gordon D Rubenfeld; B Taylor Thompson; V Marco Ranieri Journal: Intensive Care Med Date: 2012-08-25 Impact factor: 17.440
Authors: Nicole C Stowell; Jonathan Seideman; Holly A Raymond; Karen A Smalley; Roberta J Lamb; Devon D Egenolf; Peter J Bugelski; Lynne A Murray; Paul A Marsters; Rachel A Bunting; Richard A Flavell; Lena Alexopoulou; Lani R San Mateo; Don E Griswold; Robert T Sarisky; M Lamine Mbow; Anuk M Das Journal: Respir Res Date: 2009-06-01
Authors: Ghadimi-Moghadam A; Haghani M; Bevelacqua J J; Kaveh-Ahangar A; Mortazavi S M J; Ghadimi-Moghadam A; Mortazavi S A R Journal: J Biomed Phys Eng Date: 2020-04-01
Authors: Babak Baban; Hesam Khodadadi; Évila Lopes Salles; Vincenzo Costigliola; John C Morgan; David C Hess; Kumar Vaibhav; Krishnan M Dhandapani; Jack C Yu Journal: Ageing Res Rev Date: 2021-10-15 Impact factor: 10.895
Authors: Dóra Révész; Genís Ona; Giordano N Rossi; Juliana M Rocha; Rafael G Dos Santos; Jaime E C Hallak; Miguel Á Alcázar-Córcoles; José C Bouso Journal: Front Psychiatry Date: 2021-06-16 Impact factor: 5.435
Authors: Évila Lopes Salles; Hesam Khodadadi; Abbas Jarrahi; Meenakshi Ahluwalia; Valdemar Antonio Paffaro; Vincenzo Costigliola; Jack C Yu; David C Hess; Krishnan M Dhandapani; Babak Baban Journal: J Cell Mol Med Date: 2020-10-15 Impact factor: 5.310